The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS)
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Introduction Recently, the European Medicines Agency (EMA) received reports of suicidal thoughts and self-injury associated with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) liraglutide and semaglutide. Research design and methods Herein, we sought to evaluate suicidality associated with all GLP-1 RAs relative to other glucose-lowering agents currently approved by the United States Food and Drug Administration (FDA). Reports of suicidal ideation, "depression/suicidal", suicidal behavior, suicidal attempts, and completed suicide associated with GLP-1 RA exposure reported to the FDA between 2005 and October 2023 were obtained from the FDA Adverse Event Reporting System (FAERS). We present data using the reporting odds ratio (ROR). The ROR was considered significant when the lower limit of the 95% confidence interval (CI) was greater than 1.0. Results Disproportionate reporting of suicidal ideation and "depression/suicidal" was observed with semaglutide and liraglutide. Disproportionate reporting of suicidal behavior, suicide attempts, and completed suicide was not observed for any of the FDA-approved GLP-1 RAs. Conclusions Using the Bradford Hill criteria, however, and taking into consideration confounders, no causal link between GLP-1 RAs and suicidality exists.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Adverse drug reporting from FAERS indicates increased reporting of depression and suicidal ideation but not suicidal attempts/behavior with semaglutide and liraglutide.”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [81]
In the citing paper
“Due to confounding and the pharmacovigilance analytical approach used, causality is inconclusive.81”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [81]
In the citing paper
“with no recorded cases of suicidal behaviors or completed suicides.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [74]
In the citing paper
“McIntyre et al. [74] analyzed the FAERS data from 2005 to October 2023, revealing a notable incidence of suicidal ideation and depression linked to semaglutide and liraglutide, with no recorded cases of suicidal behaviors or completed suicides.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [74]
Citations
Cites
Fedak, K. M., Bernal, A., Capshaw, Z. A., & Gross, S. (2015) · Emerging Themes in Epidemiology · doi:10.1186/s12982-015-0037-4 · Cited by 680
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
The Long-Term Effect of Bariatric Surgery on Depression and Anxiety
Gill, H., Kang, S., Lee, Y., Rosenblat, J. D., Brietzke, E., Zuckerman, H., & McIntyre, R. S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.12.113 · Cited by 191 · cited 1×
“…well established that some individuals who receive bariatric surgery may be at risk of new onset or recurrent depression and suicidality, suggesting the phenomenon of suicidality is not etiologi-cally related to a specific agent or class, and instead is an intrinsic risk in this population [28,29].”
BackgroundSelf-citationZheng, J., Xie, Y., Ren, L., Qi, L., Wu, L., Pan, X., Zhou, J., Chen, Z., & Liu, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101180 · Cited by 183
Mansur, R. B., Ahmed, J., Cha, D. S., Woldeyohannes, H. O., Subramaniapillai, M., Lovshin, J., Lee, J. G., Lee, J.-H., Brietzke, E., Reininghaus, E. Z., et al. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.09.056 · Cited by 164
Self-citationThe mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
Weina, H., Yuhu, N., Christian, H., Birong, L., Feiyu, S., & Le, W. (2018) · Brain Research · doi:10.1016/j.brainres.2018.04.031 · Cited by 115
McIntyre, R. S., Powell, A. M., Kaidanovich-Beilin, O., Soczynska, J. K., Alsuwaidan, M., Woldeyohannes, H. O., Kim, A. S., & Gallaugher, L. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.09.021 · Cited by 110
Self-citationGlucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101 · cited 1×
“We are not intending to review the overall safety and tolerability of GLP-1 RAs as this has been comprehensively reviewed elsewhere [13].”
BackgroundGlucagon like peptide-1 (GLP-1) likes Alzheimer’s disease
Simsir, I. Y., Soyaltın, U. E., & Çetinkalp, Ş. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.002 · Cited by 96
Research works printed but not linked: 1
- Tenny S, Hoffman MR. Odds ratio. St. Petersburg (Florida): StatPearls Publishing; 2023.
Cited by
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
“81 Most studies have evaluated monotherapeutic agonists.”
Kornelius, E., Huang, J.-Y., Lo, S.-C., Huang, C.-N., & Yang, Y.-S. (2024) · Scientific Reports · doi:10.1038/s41598-024-75965-2 · Cited by 143
“However, following the adjustment for potential confounding factors, they concluded that no causal link exists between GLP-1 RAs and suicidality 37 .”
BackgroundGhusn, W., & Hurtado, M. D. (2024) · Obesity Pillars · doi:10.1016/j.obpill.2024.100127 · Cited by 122
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Schoretsanitis, G., Weiler, S., Barbui, C., Raschi, E., & Gastaldon, C. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.23385 · Cited by 107
Metadata
- Authors
- McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., & Kwan, A. T. H.
- Affiliations
- University of Toronto (CA)
- University Health Network (CA)
- University of Ottawa (CA)
- Corresponding author
- McIntyre, Roger S.
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2023-12-19
- Volume
- 23
- Issue
- 1
- Pages
- 47-55
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W4389681767
- Cited by
- 126
- References
- 25
- Citations by year
- 2026: 31 · 2025: 52 · 2024: 43
- FWCI
- 22.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- GLP-1 receptor agonists, suicidality, liraglutide, semaglutide, suicidal ideation, adverse drug reactions, drug safety, reporting odds ratio, suicide mortality
- MeSH terms
- Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Hypoglycemic Agents, Suicide, United States, United States Food and Drug Administration, Glucagon-Like Peptide 1, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). https://app.cochat.ai/papers/10.1080/14740338.2023.2295397
- The paper
- McIntyre, R. S., Mansur, R. B., Rosenblat, J. D., & Kwan, A. T. H. (2024). The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2023.2295397
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.